Sting and p53 DNA repair pathways are compromised in Alzheimer's disease

Thomas J Nelson1, Yunhui Xu2

  • 1Department of Neurology, Marshall University Joan C. Edwards School of Medicine, Huntington, WV, 25704, USA. nelsonth@marshall.edu.

Scientific Reports
|May 23, 2023
PubMed

Insights

Alzheimer's disease (AD) involves DNA damage, with compromised p53 protein oligomerization hindering double-strand DNA break (DSB) repair. Oxidative stress and impaired DNA repair pathways contribute to neuronal loss in AD.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Alzheimer's disease (AD) is the leading cause of dementia, characterized by DNA damage in neurons.
  • Neurons, being post-mitotic, have limited repair mechanisms for hazardous double-strand DNA breaks (DSBs).
  • The role of increased DNA damage versus impaired DNA repair in AD pathogenesis is unclear.

Purpose of the Study:

  • To investigate the status of p53 oligomerization and DNA repair pathways in Alzheimer's disease.
  • To determine if oxidative stress contributes to DNA damage and repair deficits in AD.
  • To explore the implications of impaired DNA repair signaling in AD progression.

Main Methods:

  • Analyzed p53 monomer:dimer ratio in temporal lobes of AD patients and controls.
  • Utilized in vitro oxidation of p53 and COMET assay to assess DNA damage and repair.
  • Measured levels of DNA repair proteins (14-3-3σ, γ-H2AX, ATM) and oxidative stress markers (protein carbonylation).
  • Investigated cGAS-STING-interferon signaling pathway activation in response to DSBs.

Main Results:

  • Increased monomer:dimer ratio of phosphorylated p53 in AD brains indicates compromised oligomerization.
  • Elevated DNA degradation (COMET test) and protein carbonylation suggest increased oxidative stress and DNA damage/repair inhibition.
  • Upregulation of DNA repair markers (γ-H2AX, ATM) and support proteins (14-3-3σ) observed.
  • Impaired cGAS-STING-interferon signaling with STING depletion and lack of interferon response despite DSBs.

Conclusions:

  • Oxidative stress may impair the DNA damage response (DDR) by altering p53 oligomerization, hindering DSB repair in AD.
  • Failure of immune-stimulated DNA repair pathways contributes to neuronal loss in Alzheimer's disease.
  • Targeting p53 oligomerization and DNA repair mechanisms presents potential therapeutic strategies for AD.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
541
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226